@article{ATM14034,
author = {Monica Venere},
title = {Getting down to the FACT: therapeutic targeting of MYC-dependent tumors},
journal = {Annals of Translational Medicine},
volume = {5},
number = {7},
year = {2017},
keywords = {},
abstract = {The MYC oncogene is thought to be involved in more than half of all human tumors and hence has great potential as a targeted therapy. However, despite the well appreciated role of oncogenes in the pathogenesis and maintenance of tumors, the ability to directly target them has proven elusive save a few examples, such as imatinib for chronic myelogenous leukemia. Recently, Carter et al. reported a way to circumvent the necessity to directly target MYC in neuroblastoma, a MYC-driven pediatric cancer, by identifying a downstream factor that was essential for the high expression of MYC-targeted genes in these tumors (1).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/14034}
}